ClinicalTrials.gg
RecruitingNCT06434480Updated Nov 13, 2026

SBRT in HCC With Oligoprogression on First-line Immunotherapy

An interventional study of Stereotactic Body Radiation Therapy (SBRT) in HCC, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Nov 13, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

HCC is a huge healthcare burden in Hong Kong and is one of the top 5 cancers in terms of incidence and mortality in Hong Kong. Patients with advanced HCC are treated with immunotherapy-based as first-line treatment as a standard of care. At the moment, there is limited evidence to guide subsequent treatments after patients progressed on immunotherapy. Oligoprogression is a term used to describe patients who had limited progression (usually less than 3 sites) on systemic therapy, with the rest of the lesions controlled. Previous studies in non-HCCs have shown that addition of locoregional treatment (e.g. radiotherapy) may prolong the use of systemic therapy, resulting in improved survival, but this has been relatively unexplored for HCC. In this prospective, single-arm study, we aim to evaluate the treatment outcome, efficacy and safety of the addition of radiotherapy to oligoprogressive sites for patients who had limited progression on First-line Immunotherapy.

02

Conditions studied

  • HCC

Keywords

  • SBRT in HCC
03

In context

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥ 18 years old
  2. performance 0 to 1
  3. Confirmed diagnosis of HCC
  4. Oligoprogression on immunotherapy, as defined as ≤ 5 lesions (intra- and extrahepatic lesions all together; vascular tumor thrombus is counted as one lesion)

    • First-line immunotherapy that are allowed in this study include atezolizumab plus bevacizumab, durvalumab plus tremelimumab, durvalumab, nivolumab and ipilimumab, which are approved by the FDA and have been used in Hong Kong.
  5. Progressed lesion(s) amenable to SBRT:

    • For intrahepatic progression:

      • Number of intrahepatic progression ≤ 5
      • Total intrahepatic tumours ≤ 10
      • Maximum sum of HCC ≤ 20cm
      • Any one HCC ≤ 20cm
      • Normal liver volume minus intrahepatic GTV > 700cc
      • Mean liver dose ≤ 15Gy
      • No measurable common or main branch biliary duct involvement
      • No direct tumor invasion into the stomach, duodenum, small bowel or large bowel
    • For extrahepatic progression:

      • Maximal tumor size ≤ 7cm
      • Respective dose constraints of organ at risks as listed on the UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy can be met and ASTRO guideline.
  6. Prior radiofrequency ablation (RFA) or trans-arterial chemoembolization (TACE) are eligible
  7. A liver function
  8. longer than 12 weeks
  9. At least one measurable treatment lesion according to 1.1
  10. Written must be obtained prior to any study related procedures
  11. Adequate haematological function ( ≥ 8.5g/dL; Plt ≥ 50x10\^9/L; ≥ 1.0x10\^9/L; ≤ 1.5)
  12. Adequate hepatic function (albumin ≥ 28g/L; ≤ 2.5xULN; \< 5 times upper limit normal)
  13. Adequate renal function (serum creatinine ≤ 1.5 times the ; Na ≥ 130mmol/L; K ≥ 3.0mmol/L)
  14. Able to read, understand and provide written consent

Exclusion criteria

Exclusion Criteria:

  1. History of another except appropriately-treated BCC of skin or CIN of cervix during the last 5 years
  2. Previous radiotherapy to the abdomen
  3. Previous yttrium-90 chemoembolization
  4. Repetitive history of non-healing wounds or ulcers within 2 months of inclusion
  5. Pregnant or lactating females at any time during the study
  6. Active disease requiring systemic therapy in the past 2 years
  7. Diagnosis of immunodeficiency (including )
  8. Ongoing therapy >10mg prednisone daily
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Radiotherapy

    Suitable patients are consented and enrolled with the following treatment being given. * Continue of immunotherapy till next progression, intolerability, or death as per standard practice. * Radiotherapy will start 4 to 6 weeks after consent * For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks is generally recommended. * For extrahepatic progression: delivery of ablative dose (i.e. BED10≥100Gy) will be attempted. * Lower doses to be delivered (for both intrahepatic and extrahepatic lesions) based on nearby OAR dose constraints are allowed. The final dose and fractionation are at the discretion of the treating oncologist. * Bevacizumab will need to be withhold 4 weeks prior and after radiotherapy. PD-1 or PD-L1 therapy are allowed to be continued as per the latest ESTRO-ESMO consensus guideline. * Dose constraints to organ at risk (OAR) will take reference from RTOG-1112 and UK 2022 consensus on normal tissue dose-volume constraints and ASTRO 2022 guideline.

    Radiation: Stereotactic Body Radiation Therapy (SBRT)

Interventions

  • RadiationStereotactic Body Radiation Therapy (SBRT)

    * For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks is generally recommended. * For extrahepatic progression: delivery of ablative dose will be attempted.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) with the addition of SBRT to oligo-progressive sites

    Time frame: 2 years

Secondary outcomes

  1. Overall survival (OS)

    Time frame: 2 years

  2. Objective response rates (ORR) of the irradiated lesion(s)

    Time frame: 2 years

  3. Overall objective response rates (ORR)

    Time frame: 2 years

  4. Additional treatment related adverse events (TRAE)

    Time frame: 2 years

  5. Pattern of progression

    Four types of progression pattern: * EHG (extrahepatic growth) * IHG (intrahepatic growth) * NEH (new extrahepatic lesion) * NIH (new intrahepatic growth)

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Mar 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
May 30, 2024
StartActual
Jun 21, 2024
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
30→27
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Enrollment 30→27
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06434480
Responsible party
Landon Chan (Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
May 30, 2024
Start date
Jun 21, 2024
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Landon L CHAN, MBChB, MSc
Contact
landon.chan@cuhk.edu.hk
3505 1042
Natalie KWONG, RN
Contact
nataliekwong019@cuhk.edu.hk
3505 1040

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion